39 results about "Ischaemic heart disease" patented technology

A narrowing intraluminal stent is disclosed and comprises a hollow body and a flow passage therethrough, the hollow body designed for intraluminal placement and having at least one portion of an inner cross sectional dimension smaller than the cross sectional dimension of the lumen, so as to artificially narrow a passage through the body lumen. A method of artificially narrowing a passage through a body lumen using the stent is also disclosed.

An implantable medical device system for detecting cardiac conditions such the long-term ischemic heart disease, an occlusion of a coronary artery by a thrombus or an impending as a myocardial infarction. The implantable medical device (IMD) system includes a sensor that outputs a blood flow rate signal representing a rate of blood flow through a coronary sinus of a patient's heart. An implantable medical device (IMD) includes a microcomputer circuit configured to analyze the blood flow rate signal and detect a cardiac condition as a function of the blood flow rate signal. The system can also includes an implantable lead that senses electrical activity from the patient's heart. The microcomputer circuit monitors an ST segment of the electrical activity signal and detects a cardiac condition as a function of blood flow rate signal in conjunction with the electrical activity signal.

The present invention relates to microRNA (miRNA) compounds for use in the treatment of consequences of acute ischemia / reperfusion, a method for preparing miRNA compounds by using test ischemia-reperfusion, test preconditioning and test postconditioning of biological samples, use of the miRNA compounds in the preparation of pharmaceutical compositions having cytoprotective and / or anti-ischemic effect in ischemic cardiac diseases.

A region of interest is set at a thin layer on the inside of the left ventricular wall for ecocardiographical apical long-axis tomographic images obtained while at rest, and the strain rate of the set region of interest is calculated. The value of a discriminant function is determined on the basis of a plurality of strain rates of an intermediate portion of the systolic phase. Ischemic heart disease is then diagnosed according to the value of the discriminant function.

The invention discloses an application of a medicine of anthropogenic adiponectin spherical fragment in curing diabetic-anemic cardiopathy. A gene sequence of the anthropogenic adiponectin spherical fragment obtained by the invention absolutely accords with a known gene sequence, and compared with the full-length adiponectin, the hydrolyzed anthropogenic adiponectin spherical fragment has stronger biological activity, fast reaction after dosage, good bioavailability and better clinic application prospect, especially when the diabetes patient receives a recanalization treatment after a myocardial infarction, the anemically myocardial damage of the diabetes patients can be eased by the exogenetic dosage.

The invention relates to an exosome derived from a mesenchymal stem cell. The exosome is prepared by intermittent hypoxic stimulation of the mesenchymal stem cell. The exosome prepared from the invention has stronger tissue and organ ischemia-reperfusion injury protective effect, and the biological effect of unit exosomes is improved, and treatment of diseases such as ischemic heart disease is more facilitated.

The invention discloses a traditional Chinese medicine combination used for curing heart disease, which is characterized in that the invention is prepared by the following compositions in portions by weight: 60-100 portions of rehmanniae vaporata, 30-50 portions of Chinese yam rhizome, 30-50 portions of common macrocarpium, 13-18 portions of cortex moutan, 13-18 portions of China root green birer rhizome, 13-18 portions of alisma orientale, 8-12 portions of cassia bark, 2-5 portions of hairy antler, 2-5 portions of tortoise plastron, 1-3 portions of schisandra chinensis and 1 portion of amomum villosum powder. The invention essentially cures coronary heart disease, pulmonary heart disease, rheumatic heart disease as well as hypertensive heart disease and congenital heart disease; the invention reaches 100 percent efficiency and 95 percent cure rate within one year when the heart disease attacks; symptoms of 5 percent of aged patients and patients who have two long duration of disease and systemic failure can be promoted, thus prolonging life-span.

A method of assessing a subject for aberrant cardiac function is described. The method particularly involves the measurement of a plasma biomarker, namely metallopeptidase angiotensin-converting enzyme 2 (ACE2), implicated in ischaemic heart disease.

Disclosed is a Chinese medicament for treating rheumatic heart disease, wherein the recipe includes Chinese angelica root 15g, root of herbaceous peony 15g, poria cocos wolf 20g, dragon's bone 20g, spiny jujuba seed 20g, ginseng 6g, root of red rooted saliva 20g, safflower 6g, wolfberry fruit 15g, honey-fried licorice root 6g, wherein the ginseng can be substituted by pseudostellaria root 20g or radix adenophorae 20g. The medicament is prepared through conventional processes with easy accessibility of raw materials, simplified formulation and preparing procedures, and low cost of medicament production.

The invention experimentally proves that IL-37 can obviously enhance pulmonary fibrosis in vitro cell experiments and in vivo animal models. The invention further verifies experimentally that IL-37 promotes fibrosis through TGF-beta-ALK1 access. Therefore, through the discovery of the invention, the TGF-beta signal access can be inhibited by controlling the level of IL-37, and accordingly fibrosisof internal organs can be inhibited. In this way, IL-37 can serve as a treatment target site to treat fibrosis related diseases, such as idiopathic pulmonary fibrosis, ischemic heart diseases, viralliver cirrhosis and acute pancreatitis. According to the discovery of the invention, IL-37 has the obvious effect of worsening fibrosis in vitro fibrosis cell culture and in vivo animal models, meanwhile, IL-37 provides a direction for treatment of mice pulmonary fibrosis by serving as a new treatment target site for treating fibrosis related diseases. A more direct, effective and specific methodfor treating fibrosis is provided.

The invention provides a Chinese medicine composition capable of effectively treating diabetic heart disease, belonging to the field of Chinese medicines. The Chinese medicine composition for treating diabetic heart disease is characterized by being prepared from the Chinese medicinal herbs in parts by weight: 12 parts of kudzu vine root, 12 parts of citrus chirocarpus, 20 parts of American ginseng, 15 parts of cassia twig, 15 parts of semen lepidii, 10 parts of white mulberry root bark, 8 parts of lignum dalbergiae odoriferae, 8 parts of rhizoma corydalis, 12 parts of safflower carthamus, 10 parts of flos rosae rugosae, 12 parts of arillus longan, 15 parts of concha margaritiferallsta, 25 parts of hawthorn leaf, 12 parts of sandalwood, 15 parts of tuber fleeceflower root and 20 parts of spina date seed. The Chinese medicine composition is prepared from natural Chinese medicinal herbs as raw materials, is used for treating the diabetic heart disease by using combined action of all Chinese medicinal herbs, has no toxic and side effects to a human body, and has the advantages of low cost and accurate treatment effect. In 50 patients in clinical tests, the Chinese medicine composition takes the effect in 35 patients, has the effect in 11 patients, and has no effects in 4 patients, thus the total effective rate is 96 percent.

Carnitine derivatives of formula (I) are described in racemic and / or optically active form, as well as the process for their preparation and their use as pharmaceutical anti-angina active ingredients for the treatment of ischaemic heart disease. Also described is a process for producing the (R)-carnitine enantiomer from (S)-carnitine (or vice versa), using the derivatives of formula (I).

The invention relates to a medicine that is a mongolian medicine for treating ischemic heart disease. The invention is characterized in that the medicine is made from raw medicines by weight parts as follows: Fructus Choerospondiatis is 1200 to 1500 parts, borneol is 5 to 20 parts, artificial musk is 0.2 to 1.8 parts, and Radix Aucklandiae is 100 to 500 parts. The medicine which is called as a cardiac blood shutong capsule in clinical experiments has the functions of promoting circulation of Qi and blood, invigorating pulse and analgesia, dilating coronal blood vessels, increasing coronary flow, etc., has significant curative effect on the ischemic heart disease in the types of coronary heart disease, angina pectoris, palpitation, chest distress, short breath, hypodynamia, etc., and has the advantages of quick results, long efficiency, low toxic and side effects, being suitable for treatment and nourishing, etc., and the application prospect is very considerable.

The invention discloses a traditional Chinese medicine preparation used for treating rheumatic heart disease and pertains to the traditional Chinese medicine field. The Chinese medicine preparation consists of the following active ingredients: 20g to 30g of Tuckahoe, 10g to 20g of radices saussureae, 10g to 20g of fructus aurantii immaturus, 5g to 15g of safflower, 5g to 15g of cassia twig, 5g to 15g of lilyturf root, 5g to 15g of radix bupleuri, 3g to 8g of semen nelumbinis, 3g to 8g of gardenia, 3g to 8g of fructus meliae toosendan, 3g to 8g of bezoar and 3g to 8g of cinnamon. The traditional Chinese medicine preparation used for treating rheumatic heart disease can invigorate vital energy, nourish the heart, warm yang, recover the pulse, benefit vital energy, promote blood circulation and has the advantages of determined curative effect, quick results, low cost and having no side effects on persons and the like.

The invention provides application of piRNA and antisense nucleic acid thereof in diagnosis, prevention, treatment and prognosis evaluation of an ischemic heart disease. The piRNA provided by the invention is a nucleic acid containing a sequence shown in SEQ ID No.2 or a bioactive functional fragment or variant thereof; the piRNA can be taken as a new biomarker and applied to diagnosis and / or prognosis evaluation of the ischemic heart disease; besides, the antisense nucleic acid of the piRNA can be taken as a novel medicine and used for preventing and / or treating the ischemic heart disease.

This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.

The present invention discloses a traditional Chinese medicine for treatment of diabetic cardiomyopathy, including the following raw materials by weight: 12-15 parts of angelica sinensis, 8-9 parts of pseudo-ginseng, 7-8 parts of radix scrophulariae, 12-13 parts of honeysuckle, 11-15 parts of blackend swallowwort root, 12-18 parts of lucid ganoderma, 12-15 parts of semen lepidii, 8-10 parts of cortex mori, 6-8 parts of lignum dalbergiae odoriferae, 8-12 parts of rhizoma corydalis, 15-20 parts of codonopsis pilosula, 10-15 parts of licorice, 10-15 parts of radix ophiopogonis, and 20-30 parts of lodestone. The present invention takes natural Chinese medicines as raw materials, and makes use of the combined action of each medicine for treatment of coronary atherosclerotic heart disease. The medicine has no toxic side effects on human bodies, and is inexpensive and effective.

The invention discloses a Chinese medicament for treating diabetic heart disease, which belongs to the field of Chinese medicaments for treating diabetes and has good effect and quick response. The Chinese medicament is prepared from raw materials such as citron fruit, Chinese angelica, root of pseudo-ginseng, swallowwort root, glossy ganoderma, root of red rooted salvia and the like. The Chinese medicament has the effects of supporting right and banking up root, tonifying qi and nourishing blood, replenishing the vital essence and removing heat, promoting blood circulation and removing blood stasis, and has the advantages of remarkable effect, definite curative effect and quick response.

The invention relates to a Chinese medicament for treating diabetic heart diseases, and belongs to the field of Chinese medicaments for treating cardiovascular and cerebrovascular system diseases. The Chinese medicament aims to have good effect and quick response. The Chinese medicament is prepared from raw materials such as dwarf lilyturf tuber, Chinese angelica, heterophylly falsestarwort root, radix rehmanniae, radix pseudo-ginseng, nutgrass galingale rhizome, salivia chinensis, glossy ganoderma and the like. The Chinese medicament has the effects of strengthening body resistance and archaeus, supplementing qi and nourishing blood, promoting blood circulation by removing blood stasis and stopping pain, and has the advantages of obvious effect, definite curative effect and quick response.

The invention provides a pharmaceutical composition for the treatment of rheumatic heart diseases, which is characterized by comprising the following components in parts by weight: 20-40 parts of radix pseudostellariae, 10-20 parts of atractylodes poria, 10-20 parts of poria, 2-7 parts of licorice roots, 5-15 parts of peach kernels, 1-8 parts of flos carthami, 20-35 parts of humulus scandens, 20-30 parts of caulis spatholobi, and 20-38 parts of herba taxilli. The pharmaceutical preparation disclosed by the invention has the effect of benefiting qi for activating blood circulation. The pharmaceutical composition is simple in components and scientific and reasonable in formula, and has an obvious therapeutic effect on the treatment of rheumatic heart diseases.

The invention discloses a traditional Chinese medicine composition for treating rheumatic heart disease, which is made of the following raw materials in grams by weight: 18-22 grams of salvia miltiorrhiza, 13-17 grams of forsythia, 23-27 grams of wild buckwheat root, Gentiana chinensis 16-20 grams, mulberry branch 8-12 grams, xihe willow 3-7 grams, almond 13-17 grams, mountain bean root 8-12 grams. The invention aims to provide a traditional Chinese medicine composition for treating rheumatic heart disease with convenient preparation and obvious effect.

The invention relates to a medicine for treating rheumatic heart disease. The medicine is prepared from the following medicinal raw materials in parts by weight: 22 parts of caudate sweetleaf roots, 12 parts of radix euphorbiae, 9 parts of cortex erythrinae, 7 parts of radix asteris, 12 parts of macrosolen bibracteolatus, 10 parts of scutellaria orthocalyx and 12 parts of herba artemisiae annuae. According to the medicine, caudate sweetleaf roots have the effects of clearing heat, inducing diuresis, cooling blood, stopping bleeding, expelling wind and relieving pain; radix euphorbiae has the effects of stopping bleeding by astringency, relieving dysentery and killing parasites; cortex erythrinae has the effects of dispelling wind, drying dampness, relaxing muscles and tendons, removing obstructionfrom meridians, killing parasites and relieving itching; radix asteris has the effects of moistening lung, descending qi, eliminating phlegm and relieving cough; macrosolen bibracteolatus has the effect of removing wind-dampness; scutellaria orthocalyx has the effects of purging internal fire, relieving asthma, removing toxicity and diminishing swelling; herba artemisiae annuae has the effects of clearing heat, inducing diuresis and removing jaundice. The medicinal materials are combined to achieve the effects of promoting blood circulation to remove blood stasis, calming heart, tonifying lung, warming yang, inducing diuresis, tonifying qi and consolidating depletion. The medicine can be used for safely and effectively treating rheumatic heart disease.

The invention discloses a drug for treatment of rheumatic heart disease, which is prepared with the following raw materials: bupleurum root, stem, toosendan fruit, baikal skullcap root, charred triplet, nutagrass flatsedge rhizome and fructus polygoni orientalis. The invention has good use effect, accurate therapeutic effect, and over 70 percent of effective rate.